Dear Visitor:

Thank you for visiting www.CellGenesys.com. Whether you are an investor wanting to learn about our business, a patient seeking information about our clinical trials, a potential collaborator or a job seeker, we hope that this site provides you with the information you are looking for. If you are a first time visitor, welcome; and if you are returning to our site, welcome back!

Cell Genesys' clinical stage product portfolio, which currently includes four product candidates, is based on two product platforms: GVAX™ cancer immunotherapies and oncolytic virus therapies. Our state-of-the-art GMP manufacturing facility is in place to manufacture GVAX immunotherapies, beginning with GVAX immunotherapy for prostate cancer which is currently being evaluated in multicenter Phase 3 clinical trials in patients with advanced-stage prostate cancer. We are pleased to continue to be well positioned financially to pursue multiple product candidates in parallel with the goal of bringing new treatment options to cancer patients as quickly as possible.

Cell Genesys continues to have a strong balance sheet, an equity interest in our former subsidiary, Ceregene, Inc., and a state-of-the-art manufacturing infrastructure.

Thank you for taking the time to visit our web site to learn more about Cell Genesys. We encourage you to visit the site on a regular basis to ensure you remain current with the Cell Genesys story. Should you have any questions that are not answered on our web site, you are welcome to contact us at ir@cellgenesys.com.